New Kid Tmunity Banks $100M From Gilead and Facebook Billionaire Sean Parker
The funds raised will partly go towards funding two clinical trials that have already opened. Source: BioSpace
Bay Area's GigaGen Moves to New Space to Accommodate Growth
GigaGen completed relocation to One Tower Place in late December 2017. Source: BioSpace
3 Biotechs That Have Doubled Investors' Money in Less Than a Year
Having a stock double in value is a good thing. Source: BioSpace
Gilead's Kite Pays $135M for Ex-Agensys R&D Building
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County. Source: BioSpace
Amgen Jumps as Migraine Drug Wows in Late-Stage Study
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace
Idera, Biocryst Tie the Knot and Transform Into a Rare Disease Pharma
The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board. Source: BioSpace
Bay Area's Adamas Pharma Pays Big Bucks to Double HQ
With the commercial launch of newly-approved Parkinson's disease treatment Gocovri, Bay Area drugmaker Adamas is growing. Source: BioSpace
3 Diabetes Biotechs That Could Surge 50% or More in 2018
Wall Street projects these three biotechs will grow the fastest over the next 12 months. Source: BioSpace
Deal Spree Continues as Celgene Nabs Juno in $9B Deal
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace
Hepatares Co-Founder to Helm Merck's New R&D Center in the UK
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace
- Go to the previous page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- …
- 288
- Go to the next page